MMP-2 Responsive Gold Nanorods Loaded with HSP-70 siRNA for Enhanced Photothermal Tumor Therapy.

Autor: Sun R; School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.; Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Beijing Laboratory of Biomedical Materials, Beijing 100069, China.; Laboratory for Clinical Medicine, Capital Medical University, Beijing 100069, China., Wang Y; School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.; Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Beijing Laboratory of Biomedical Materials, Beijing 100069, China.; Laboratory for Clinical Medicine, Capital Medical University, Beijing 100069, China., Sun Q; School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.; Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Beijing Laboratory of Biomedical Materials, Beijing 100069, China.; Laboratory for Clinical Medicine, Capital Medical University, Beijing 100069, China., Su Y; Laboratory for Clinical Medicine, Capital Medical University, Beijing 100069, China.; Medical Oncology Department, Pediatric Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China., Zhang J; School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.; Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Beijing Laboratory of Biomedical Materials, Beijing 100069, China.; Laboratory for Clinical Medicine, Capital Medical University, Beijing 100069, China., Liu D; School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.; Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Beijing Laboratory of Biomedical Materials, Beijing 100069, China.; Laboratory for Clinical Medicine, Capital Medical University, Beijing 100069, China., Huo R; School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.; Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Beijing Laboratory of Biomedical Materials, Beijing 100069, China.; Laboratory for Clinical Medicine, Capital Medical University, Beijing 100069, China., Tian Y; School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.; Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Beijing Laboratory of Biomedical Materials, Beijing 100069, China.; Laboratory for Clinical Medicine, Capital Medical University, Beijing 100069, China., Baldan M; School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.; Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Beijing Laboratory of Biomedical Materials, Beijing 100069, China.; Laboratory for Clinical Medicine, Capital Medical University, Beijing 100069, China., Zhang S; School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.; Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Beijing Laboratory of Biomedical Materials, Beijing 100069, China.; Laboratory for Clinical Medicine, Capital Medical University, Beijing 100069, China., Cui C; School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.; Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Beijing Laboratory of Biomedical Materials, Beijing 100069, China.; Laboratory for Clinical Medicine, Capital Medical University, Beijing 100069, China.
Jazyk: angličtina
Zdroj: Molecular pharmaceutics [Mol Pharm] 2024 Oct 18. Date of Electronic Publication: 2024 Oct 18.
DOI: 10.1021/acs.molpharmaceut.4c00188
Abstrakt: Gold nanorods (Au NRs) are a valuable photothermal nanomaterial for tumor therapy. However, when treated with Au NRs for photothermal therapy, the expression of heat shock proteins in tumors will increase, which will induce heat resistance in tumor cells and reduce the photothermal therapeutic effect of Au NRs. By RNA interference, the expression of heat shock proteins would be effectively inhibited to improve the efficasy of tumor photothermal therapy. However, deep and noninvasive tissue penetration remains a great obstacle to applying siRNA successfully. Thus, the nanoplatform AGC/HSP-70 siRNA was designed for enhanced photothermal tumor therapy by RNA interference. In the AGC/HSP-70 siRNA complex, the Au-S bond modified the matrix metalloproteinase-2 (MMP-2)-sensitive peptide GPLGLAG on the surface of gold nanorods. Moreover, the natural basic polysaccharide (chitosan) was reacted with the peptide by an amide bond for delivering heat shock protein 70 silencing siRNA (HSP-70 siRNA). Modifying the MMP-2-sensitive linker could cause more Au NRs to accumulate in tumors to exert a photothermal effect and promote the penetration of HSP-70 siRNA and chitosan complexes into deep tumor tissues. In vitro experiments indicated that the enzymolysis of the MMP-2-sensitive linker for AGC/HSP-70 siRNA could promote the cellular uptake and perinuclear distribution of HSP-70 siRNA in tumor cells, which may be due to the smaller size and positive electricity of the complexes. All of these results ensured the efficient gene silencing effect of HSP-70 siRNA to enhance the photothermal therapeutic effect of Au NRs in tumor tissues, as demonstrated by the gene silencing and cellular apoptotic experiments. In vivo experiments further proved that the AGC/HSP-70 siRNA nanoplatform efficiently improved the photothermal effect of Au NRs. In summary, this work proved that AGC/HSP-70 siRNA is a promising drug delivery strategy for enhancing the photothermal therapy of tumors by regulating the photothermal sensitivity of deep tumor cells as well as retaining more Au NRs in tumor tissues, and also provides a novel strategy for tumor photothermal therapy.
Databáze: MEDLINE
Externí odkaz: